Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 41Stomach Neoplasms 3Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Pleuropulmonary blastoma 1Patient Preference 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Multiple Myeloma 1Lymphoma 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1HER2-positive Breast Cancer 1HER2 Positive Breast Cancer 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

lorvotuzumab mertansine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pleuropulmonary blastoma × Ado-Trastuzumab Emtansine × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡